ENTRADA THERAPEUTICS, INC. Increase (Decrease) in Prepaid Expense and Other Assets
ENTRADA THERAPEUTICS, INC. (TRDA) reported Increase (Decrease) in Prepaid Expense and Other Assets of $164.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets · last filed 2026-08-05
- ENTRADA THERAPEUTICS, INC. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-06-30 was -$2.30M.
- ENTRADA THERAPEUTICS, INC. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-03-31 was $2.46M, a 8.27% increase year-over-year.
- ENTRADA THERAPEUTICS, INC. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-12-31 was -$1.50M, a 150.59% decline year-over-year.
- ENTRADA THERAPEUTICS, INC. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-09-30 was -$3.73M, a 393.32% decline year-over-year.
- ENTRADA THERAPEUTICS, INC. increase (decrease) in prepaid expense and other assets for fiscal 2025 was -$7.64M, a 272.23% decline from fiscal 2024.
- ENTRADA THERAPEUTICS, INC. increase (decrease) in prepaid expense and other assets for fiscal 2024 was $4.44M.
- ENTRADA THERAPEUTICS, INC. increase (decrease) in prepaid expense and other assets for fiscal 2023 was -$8.62M, a 161.49% decline from fiscal 2022.
- ENTRADA THERAPEUTICS, INC. increase (decrease) in prepaid expense and other assets for fiscal 2022 was $14.02M, a 108.26% increase from fiscal 2021.
| Period end | Increase (Decrease) in Prepaid Expense and Other Assets 3 month | Increase (Decrease) in Prepaid Expense and Other Assets 6 month | Increase (Decrease) in Prepaid Expense and Other Assets 9 month | Increase (Decrease) in Prepaid Expense and Other Assets 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$2.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $164.00K 10-Q · filed 2026-08-05 | -$1.34M derived: sum of 3 quarters · filed 2026-08-05 | -$5.07M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $2.46M 10-Q · filed 2026-05-07 | $957.00K derived: sum of 2 quarters · filed 2026-05-07 | -$2.77M derived: sum of 3 quarters · filed 2026-05-07 | -$7.45M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | -$1.50M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$5.24M derived: sum of 2 quarters · filed 2026-02-26 | -$9.91M derived: sum of 3 quarters · filed 2026-08-05 | -$7.64M 10-K · filed 2026-02-26 |
| 2025-09-30 | -$3.73M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$8.41M derived: sum of 2 quarters · filed 2026-08-05 | -$6.14M 10-Q · filed 2025-11-06 | -$3.17M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | -$4.68M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$2.41M 10-Q · filed 2026-08-05 | $566.00K derived: sum of 3 quarters · filed 2026-08-05 | $1.84M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $2.27M 10-Q · filed 2026-05-07 | $5.25M derived: sum of 2 quarters · filed 2026-05-07 | $6.52M derived: sum of 3 quarters · filed 2026-05-07 | $9.39M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $2.97M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $4.25M derived: sum of 2 quarters · filed 2026-02-26 | $7.12M derived: sum of 3 quarters · filed 2026-02-26 | $4.44M 10-K · filed 2026-02-26 |
| 2024-09-30 | $1.27M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $4.14M derived: sum of 2 quarters · filed 2025-11-06 | $1.46M 10-Q · filed 2025-11-06 | -$11.05M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $2.87M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $192.00K 10-Q · filed 2025-08-06 | -$12.32M derived: sum of 3 quarters · filed 2025-08-06 | $2.45M derived: sum of 4 quarters · filed 2025-08-06 |
| 2024-03-31 | -$2.68M 10-Q · filed 2025-05-08 | -$15.20M derived: sum of 2 quarters · filed 2025-05-08 | -$418.00K derived: sum of 3 quarters · filed 2025-05-08 | -$6.96M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | -$12.52M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $2.26M derived: sum of 2 quarters · filed 2025-02-27 | -$4.28M derived: sum of 3 quarters · filed 2025-02-27 | -$8.62M 10-K · filed 2025-02-27 |
| 2023-09-30 | $14.78M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05 | $8.23M derived: sum of 2 quarters · filed 2024-11-05 | $3.89M 10-Q · filed 2024-11-05 | $5.90M derived: sum of 4 quarters · filed 2024-11-05 |
| 2023-06-30 | -$6.54M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | -$10.88M 10-Q · filed 2024-08-13 | -$8.88M derived: sum of 3 quarters · filed 2024-08-13 | $630.00K derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | -$4.34M 10-Q · filed 2024-05-07 | -$2.34M derived: sum of 2 quarters · filed 2024-05-07 | $7.17M derived: sum of 3 quarters · filed 2024-05-07 | $8.01M derived: sum of 4 quarters · filed 2024-05-07 |
| 2022-12-31 | $2.00M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-13 | $11.51M derived: sum of 2 quarters · filed 2024-03-13 | $12.35M derived: sum of 3 quarters · filed 2024-03-13 | $14.02M 10-K · filed 2024-03-13 |
| 2022-09-30 | $9.51M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $10.35M derived: sum of 2 quarters · filed 2023-11-07 | $12.02M 10-Q · filed 2023-11-07 | $18.30M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | $838.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $2.51M 10-Q · filed 2023-08-08 | $8.79M derived: sum of 3 quarters · filed 2023-08-08 | $9.46M derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | $1.67M 10-Q · filed 2023-05-10 | $7.95M derived: sum of 2 quarters · filed 2023-05-10 | $8.62M derived: sum of 3 quarters · filed 2023-05-10 | $8.34M derived: sum of 4 quarters · filed 2023-05-10 |
| 2021-12-31 | $6.28M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-06 | $6.95M derived: sum of 2 quarters · filed 2023-03-06 | $6.67M derived: sum of 3 quarters · filed 2023-03-06 | $6.73M 10-K · filed 2023-03-06 |
| 2021-09-30 | $664.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | $383.00K derived: sum of 2 quarters · filed 2022-11-07 | $449.00K 10-Q · filed 2022-11-07 | -$1.14M derived: sum of 4 quarters · filed 2022-11-07 |
| 2021-06-30 | -$281.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | -$215.00K 10-Q · filed 2022-08-11 | -$1.81M derived: sum of 3 quarters · filed 2022-08-11 | |
| 2021-03-31 | $66.00K 10-Q · filed 2022-05-12 | -$1.52M derived: sum of 2 quarters · filed 2022-05-12 | ||
| 2020-12-31 | -$1.59M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-15 | $311.00K 10-K · filed 2022-03-15 | ||
| 2020-09-30 | $1.90M 10-Q · filed 2021-12-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |